Subscribe To
VERV / Verve Therapeutics: VERVE-101 On Hold, But Technology Remains Sound
Content Topics
Verve
Therapeutics
101
Hold
Technology
Remains
Sound
Therapeutics
Verve 101
Stock
VERV
VERV News
By Zacks Investment Research
November 1, 2023
Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains?
Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revision more_horizontal
By GlobeNewsWire
September 26, 2023
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association's Scientific Sessions 2023
Company to hold investor event in conjunction with data presentation on November 12, 2023 Company to hold investor event in conjunction with data pres more_horizontal
By Zacks Investment Research
August 10, 2023
Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to l more_horizontal
By Zacks Investment Research
July 25, 2023
How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5%
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Verve Therapeutics (VERV). While the effectiveness o more_horizontal
By The Motley Fool
July 13, 2023
Cathie Wood Is Buying This Biotech, but Here's Why I'm Not
Cathie Wood has been buying a lot of Verve Therapeutics stock recently. It's a gene-editing biotech that's just starting its first clinical trials. more_horizontal
By MarketBeat
June 30, 2023
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve, which was founded in 2018 and went public in June 2021, is developing gene-editing treatments, delivered through a single, intravenous infusion more_horizontal
By Zacks Investment Research
June 20, 2023
Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly
Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease. more_horizontal
By Zacks Investment Research
May 15, 2023
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to l more_horizontal